+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Premature Ejaculation Treatment Market - Global Forecast 2026-2032- Product Image
Premature Ejaculation Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Premature Ejaculation Treatment Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968711
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Premature Ejaculation Treatment Market is projected to reach USD 3.80 Billion in 2026. It is expected to continue growing at a CAGR of 8.04%, reaching USD 6.05 Billion by 2032.

Premature ejaculation treatment is moving from a narrowly defined sexual-health intervention to a broader men’s health category shaped by urology, mental health, digital care, and pharmaceutical innovation. Premature ejaculation is recognized by major clinical bodies, including the International Society for Sexual Medicine and the American Urological Association, as one of the most common male sexual dysfunctions, with strict diagnostic studies estimating lifelong premature ejaculation at approximately 2% to 5% of men and broader self-reported concerns commonly reaching higher double-digit levels.

The treatment landscape includes behavioral techniques, psychosexual counseling, topical anesthetics, selective serotonin reuptake inhibitors used on-label in some markets and off-label in others, and adjunctive management of erectile dysfunction when present. For market participants, the opportunity is defined less by a single therapy and more by an integrated care pathway that improves diagnosis, adherence, privacy, and patient-reported outcomes.

Transformative Shifts Reshaping Premature Ejaculation Care

The most significant shift in the premature ejaculation treatment landscape is the transition from episodic product use to longitudinal, multidisciplinary care. Clinical guidance increasingly emphasizes classification by lifelong versus acquired premature ejaculation, identification of comorbid erectile dysfunction, and evaluation of psychological stressors, prostate inflammation, thyroid dysfunction, medication effects, and relationship factors.

Digital health platforms, tele-urology, discreet e-pharmacy channels, and direct-to-consumer men’s health services are reducing stigma and expanding access. At the same time, regulators and clinicians are raising the bar for evidence quality, especially for claims involving supplements, compounded formulations, and non-prescription products. Companies that combine clinical validation, patient education, and responsible digital engagement are best positioned to capture durable demand.

Cumulative Impact of Artificial Intelligence on Treatment Pathways

Artificial intelligence is becoming an enabling layer across premature ejaculation diagnosis, triage, adherence, and patient engagement. AI-supported intake tools can help standardize symptom histories, identify red flags, assess erectile dysfunction overlap, and route patients to appropriate physician-led care. In research settings, machine learning can support pattern recognition across real-world evidence, patient-reported outcomes, treatment persistence, and adverse-event signals.

The cumulative impact of AI will be strongest where it improves privacy, personalization, and clinical workflow without replacing licensed medical judgment. High-value applications include adaptive behavioral coaching, multilingual patient education, adherence reminders, and decision-support tools aligned with validated measures such as intravaginal ejaculatory latency time and patient-reported control, distress, and satisfaction outcomes.

Key Regional Insights Across Global Treatment Demand

Asia-Pacific represents a high-volume opportunity due to its large male population, expanding telemedicine infrastructure, and growing acceptance of men’s health consultations in China, India, Japan, South Korea, Australia, and ASEAN markets. Demand is shaped by urbanization, improving insurance penetration in select countries, and the availability of both prescription and over-the-counter topical options, although regulatory approval pathways and cultural stigma vary widely across the region.

North America is characterized by strong digital health adoption, high awareness of sexual wellness, and physician-guided management through urology and primary care, while the United States remains notable for the absence of an FDA-approved oral medicine specifically indicated for premature ejaculation. Europe benefits from established urology guidelines, mature reimbursement systems in key markets, pharmacovigilance standards, and experience with dapoxetine availability in several countries. Latin America is seeing rising demand through private clinics, pharmacy-based access, and growing discussion of male sexual dysfunction in Mexico and Brazil, though affordability and uneven specialist access remain important constraints. The Middle East shows increasing use of confidential private-care models and teleconsultation services, particularly in higher-income Gulf health systems, while Africa remains an emerging treatment landscape where access is closely linked to urban healthcare capacity, physician training, product affordability, and culturally sensitive education.

Key Group Insights for Strategic Market Prioritization

ASEAN markets are gaining relevance as digital pharmacies, private hospitals, and mobile-first health platforms expand access to discreet sexual-health care, although differences in regulatory enforcement, language diversity, and physician availability influence adoption. The GCC presents a premium private-care opportunity supported by high healthcare spending, medical tourism, specialist clinics, and demand for confidential consultation models that align with cultural expectations around privacy.

The European Union offers a structured environment for evidence-based urology practice, pharmacovigilance, medicine authorization standards, and cross-border regulatory consistency, while BRICS countries provide scale through large populations, expanding domestic pharmaceutical capacity, and rising digital-health access across China, India, Brazil, Russia, and South Africa. G7 countries lead in clinical research, telehealth maturity, guideline development, and quality standards, whereas NATO-aligned markets broadly benefit from developed healthcare infrastructure, clinician education networks, and harmonized evidence-based management practices that support responsible premature ejaculation treatment adoption.

Key Country Insights in Premature Ejaculation Treatment

The United States leads in telehealth commercialization, digital men’s health services, and clinical innovation, while Canada emphasizes regulated medical access, evidence-based counseling, and primary-care referral pathways. Mexico and Brazil show growing private-sector demand supported by pharmacy access, urban specialist networks, and expanding awareness of male sexual dysfunction. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established urology networks, sexual-medicine expertise, and guideline-based management, while Russia’s market is influenced by domestic prescribing practices, private-care availability, and variable access across urban and regional settings.

China and India offer substantial long-term scale as stigma declines, mobile health adoption expands, and men’s health discussions become more visible, though quality assurance, regulatory compliance, and physician-led diagnosis remain critical. Japan, South Korea, and Australia show strong potential for clinically validated, privacy-focused solutions due to high digital adoption, mature healthcare systems, and demand for discreet care. Across these countries, treatment progress depends on combining approved pharmacologic options where available, behavioral support, psychosexual counseling, erectile dysfunction assessment, and patient education that reflects local regulation, cultural expectations, and healthcare access patterns.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically credible positioning by aligning product claims with urology guidelines, validated endpoints, and transparent safety information. Companies should invest in physician education, patient screening tools, and differentiated care pathways for lifelong versus acquired premature ejaculation, particularly where erectile dysfunction, anxiety, depression, prostatitis, thyroid dysfunction, medication effects, or relationship distress coexist.

Commercial strategies should integrate telehealth, pharmacy partnerships, behavioral support, and post-treatment follow-up to improve adherence and satisfaction. Leaders should also monitor regulatory scrutiny of sexual wellness claims, build pharmacovigilance capabilities, protect patient privacy, and use real-world evidence to demonstrate tolerability, appropriate use, and patient-reported improvement.

Research Methodology and Evidence Framework

This executive summary is developed from a structured review of peer-reviewed clinical literature, urology and sexual-medicine guidelines, regulatory information, public health data, and market-access indicators. Sources considered include established medical societies, national health authorities, drug-labeling information, telehealth adoption evidence, and published epidemiological studies on premature ejaculation prevalence and treatment outcomes.

The methodology emphasizes triangulation across clinical validity, regulatory status, care-delivery trends, and regional healthcare dynamics. Market interpretation avoids unsupported forecasts and focuses on verifiable drivers, including population scale, digital health penetration, clinical practice patterns, product availability, privacy expectations, and evidence-based treatment adoption.

Conclusion: Evidence-Based Growth in Men’s Sexual Health

The premature ejaculation treatment market is entering a more sophisticated phase in which clinical evidence, digital access, patient privacy, and integrated care models define competitive advantage. Demand is supported by high unmet need, persistent stigma, and the growing normalization of men’s health discussions across both developed and emerging markets.

Sustainable growth will depend on responsible innovation. Companies that deliver physician-guided, evidence-based, culturally sensitive, and digitally enabled care will be best positioned to improve outcomes, reduce inappropriate self-treatment, and strengthen trust in this evolving therapeutic category.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Premature Ejaculation Treatment Market, by Treatment Type
7.1. Introduction
7.2. Non Pharmacological
7.2.1. Behavioral Therapy
7.2.1.1. Sensate Focus
7.2.1.2. Start Stop Technique
7.2.2. Devices
7.2.2.1. Constrictive Ring
7.2.2.2. Vibratory Stimulation
7.3. Pharmacological
7.3.1. Phosphodiesterase Inhibitors
7.3.1.1. Sildenafil
7.3.1.2. Tadalafil
7.3.2. Selective Serotonin Reuptake Inhibitors
7.3.2.1. Dapoxetine
7.3.2.2. Fluoxetine
7.3.3. Local Anesthetics
7.3.4. Combination Pills
8. Premature Ejaculation Treatment Market, by Dosage Form
8.1. Introduction
8.2. Creams
8.3. Sprays
8.4. Tablets
9. Premature Ejaculation Treatment Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Topical
10. Premature Ejaculation Treatment Market, by Onset Type
10.1. Introduction
10.2. Lifelong Premature Ejaculation
10.3. Acquired Premature Ejaculation
11. Premature Ejaculation Treatment Market, by Treatment Accessibility
11.1. Introduction
11.2. Prescription-based
11.3. Over-the-Counter (OTC)
12. Premature Ejaculation Treatment Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Premature Ejaculation Treatment Market, by Distribution Channel
13.1. Introduction
13.2. Online
13.3. Offline
14. Premature Ejaculation Treatment Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Premature Ejaculation Treatment Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Premature Ejaculation Treatment Market, by Country
16.1. United States
16.2. China
16.3. Germany
16.4. Japan
16.5. India
16.6. United Kingdom
16.7. France
16.8. Canada
16.9. Italy
16.10. Brazil
16.11. Australia
16.12. Mexico
16.13. South Korea
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Absorption Pharmaceuticals LLC
18.3. Alembic Pharmaceuticals Limited
18.4. Alkem Laboratories Ltd.
18.5. AstraZeneca PLC
18.6. Bayer AG
18.7. Church & Dwight Co., Inc.
18.8. Cipla Limited
18.9. Dr. Reddy’s Laboratories Ltd.
18.10. Emcure Pharmaceuticals Ltd.
18.11. Endo International plc
18.12. Futura Medical plc
18.13. Hetero Drugs Ltd.
18.14. Incepta Pharmaceuticals Ltd.
18.15. Intas Pharmaceuticals Ltd.
18.16. Lupin Limited
18.17. Macleods Pharmaceuticals Ltd.
18.18. Mankind Pharma Ltd.
18.19. Menarini Group
18.20. Merck KGaA
18.21. Niksan Pharmaceutical
18.22. Panacea Biotec Ltd.
18.23. Plethora Solutions Ltd.
18.24. Reckitt Benckiser Group plc
18.25. Regent Pacific Group Limited
18.26. Sandoz International GmbH
18.27. Sun Pharmaceutical Industries Ltd.
18.28. Taj Pharma India Ltd.
18.29. Teva Pharmaceuticals Industries Ltd.
18.30. Torrent Pharmaceuticals Ltd.
18.31. Viatris Inc.
18.32. Zydus Lifesciences Ltd.
List of Figures
FIGURE 1. GLOBAL PREMATURE EJACULATION TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PREMATURE EJACULATION TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PREMATURE EJACULATION TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PREMATURE EJACULATION TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL PREMATURE EJACULATION TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL BEHAVIORAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL BEHAVIORAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL BEHAVIORAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SENSATE FOCUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SENSATE FOCUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SENSATE FOCUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL START STOP TECHNIQUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL START STOP TECHNIQUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL START STOP TECHNIQUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CONSTRICTIVE RING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CONSTRICTIVE RING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CONSTRICTIVE RING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL VIBRATORY STIMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL VIBRATORY STIMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL VIBRATORY STIMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PHOSPHODIESTERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PHOSPHODIESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PHOSPHODIESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SILDENAFIL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SILDENAFIL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SILDENAFIL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TADALAFIL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TADALAFIL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TADALAFIL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL DAPOXETINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL DAPOXETINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL DAPOXETINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL FLUOXETINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL FLUOXETINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL FLUOXETINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL COMBINATION PILLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL COMBINATION PILLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL COMBINATION PILLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL SPRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SPRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SPRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL LIFELONG PREMATURE EJACULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL LIFELONG PREMATURE EJACULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL LIFELONG PREMATURE EJACULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ACQUIRED PREMATURE EJACULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ACQUIRED PREMATURE EJACULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ACQUIRED PREMATURE EJACULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PRESCRIPTION-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PRESCRIPTION-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PRESCRIPTION-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL OVER-THE-COUNTER (OTC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL OVER-THE-COUNTER (OTC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL OVER-THE-COUNTER (OTC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 117. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 118. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 119. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 120. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 121. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 122. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 123. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 124. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 125. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 126. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 127. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 128. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 157. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 159. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 160. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 161. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 162. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 163. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 164. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 165. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 166. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 167. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 168. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 169. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 188. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 189. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 190. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 191. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 192. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 193. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 194. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 195. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 197. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 198. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 202. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 203. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 204. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 205. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 206. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 207. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 208. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 209. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 211. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 212. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 230. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 231. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 232. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 233. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 234. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 235. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 236. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 237. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 239. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 240. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 242. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 243. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 244. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 245. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 246. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 247. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 248. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 249. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 250. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 251. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 253. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 254. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 256. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 257. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 258. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 259. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 260. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 261. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 262. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 263. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 264. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 265. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 266. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 267. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 268. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 287. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 288. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 289. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 290. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 291. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 292. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 293. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 294. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 295. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 296. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 297. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 301. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 302. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 303. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 304. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 305. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 306. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 307. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 308. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 309. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2017-2032 (USD MILLION)
TABLE 310. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2017-2032 (USD MILLION)
TABLE 311. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 313. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 315. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 316. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2017-2032 (USD MILLION)
TABLE 317. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2017-2032 (USD MILLION)
TABLE 318. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 319. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 320. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 321. JAPAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 322. JAPAN PREMATURE EJACULATION TREATMEN

Companies Mentioned

  • AbbVie Inc.
  • Absorption Pharmaceuticals LLC
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Church & Dwight Co., Inc.
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Endo International plc
  • Futura Medical plc
  • Hetero Drugs Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Mankind Pharma Ltd.
  • Menarini Group
  • Merck KGaA
  • Niksan Pharmaceutical
  • Panacea Biotec Ltd.
  • Plethora Solutions Ltd.
  • Reckitt Benckiser Group plc
  • Regent Pacific Group Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Taj Pharma India Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.8 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.05 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Premature Ejaculation Treatment - Global Strategic Business Report - Product Image

Premature Ejaculation Treatment - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Premature Ejaculation Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Premature Ejaculation Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 182 Pages
  • Global
From
Premature Ejaculation Treatment Market Report 2026 - Product Image

Premature Ejaculation Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Premature Ejaculation Epidemiology Forecast 2026-2035 - Product Image

Premature Ejaculation Epidemiology Forecast 2026-2035

  • Report
  • 100 Pages
  • Global
From
2025 Global Forecast for Premature Ejaculation Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Premature Ejaculation Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From

About the Premature Ejaculation Drug Market

The Premature Ejaculation Drug market is a subset of the Sexual and Reproductive Health Drugs market. It is composed of drugs used to treat premature ejaculation, a condition in which a man ejaculates too quickly during sexual intercourse. These drugs are typically taken orally and work by increasing the time it takes for a man to ejaculate. Common side effects of these drugs include dizziness, headache, and nausea. The Premature Ejaculation Drug market is growing due to increased awareness of the condition and the availability of treatments. This has led to an increase in demand for these drugs, as well as an increase in research and development of new drugs. Some companies in the Premature Ejaculation Drug market include Pfizer, Eli Lilly, and Johnson & Johnson. These companies are involved in the research, development, and marketing of drugs to treat premature ejaculation. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.